Of the 24 HER2-positive BC patients, 16 (67%) received taxanes plus carboplatin plus trastuzumab plus pertuzumab and 8 (33%) received taxanes plus carboplatin plus trastuzumab treatment. The gene discussed is ERBB2; the disease is breast cancer.